Extreme Response to High-dose Testosterone in BRCA2- and ATM-mutated Prostate Cancer.
Department of Oncology, Johns Hopkins Medicine, Baltimore, MD, USA.
Benjamin A
BA
Teply
Department of Oncology, Johns Hopkins Medicine, Baltimore, MD, USA.
Sushant
S
Kachhap
Department of Oncology, Johns Hopkins Medicine, Baltimore, MD, USA.
Mario A
MA
Eisenberger
Department of Oncology, Johns Hopkins Medicine, Baltimore, MD, USA. Electronic address: denmesa@jhmi.edu.
Samuel R
SR
Denmeade
D000368:Aged; D018931:Antineoplastic Agents, Hormonal / Q000008:administration & dosage*; D064007:Ataxia Telangiectasia Mutated Proteins / Q000235:genetics*; D024682:BRCA2 Protein / Q000235:genetics*; D014408:Biomarkers, Tumor / Q000235:genetics*; D016368:Frameshift Mutation; D020022:Genetic Predisposition to Disease; D006801:Humans; D008297:Male; D020125:Mutation, Missense; D060787:Neoplasm Grading; D010641:Phenotype; D064129:Prostatic Neoplasms, Castration-Resistant / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology; D013739:Testosterone / Q000008:administration & dosage / Q000031:analogs & derivatives*; D016896:Treatment Outcome
D018931:Antineoplastic Agents, Hormonal; D024682:BRCA2 Protein; C551750:BRCA2 protein, human; D014408:Biomarkers, Tumor; D013739:Testosterone; C576324:ATM protein, human; D064007:Ataxia Telangiectasia Mutated Proteins; C016131:testosterone 17 beta-cypionate
Cell. 2015 May 21;161(5):1215-1228
26000489
Nature. 2005 Apr 14;434(7035):917-21
15829967
Sci Transl Med. 2015 Jan 7;7(269):269ra2
25568070
N Engl J Med. 2015 Oct 29;373(18):1697-708
26510020
N Engl J Med. 2016 Aug 4;375(5):443-53
27433846